NasdaqCM:ONCYBiotechs
Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant mCRC Regimen
On February 4, 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, microsatellite-stable metastatic colorectal cancer.
The designation is backed by clinical data showing pelareorep-based therapy delivered higher response rates and longer survival measures than existing standard-of-care options in this hard-to-treat subgroup.
With the FDA’s Fast Track Designation in place,...